TY  - JOUR
T1  - İmmün Kontrol Noktası İnhibitörleri Ctla-4 ve Pd-1/Pd-l1’in İmmünoterapideki Yeri
TT  - Immune Checkpoint Inhibitors: Ctla-4 and Pd-1/Pd-l1 in Immunotherapy
AU  - Kahveci, Kübra
AU  - Türkoğlu, Melisa
PY  - 2019
DA  - December
Y2  - 2019
DO  - 10.29048/makufebed.569375
JF  - Mehmet Akif Ersoy Üniversitesi Fen Bilimleri Enstitüsü Dergisi
JO  - MAKUFEBED
PB  - Burdur Mehmet Akif Ersoy University
WT  - DergiPark
SN  - 1309-2243
SP  - 210
EP  - 218
VL  - 10
IS  - 2
LA  - tr
AB  - Kanser immünoterapisi,kanserle mücadelede insan immün sistemini güçlendirmeyi amaçlar ve immünsistemin kanser ile normal hücreler arasındaki en iyi biyokimyasalfarklılıkları tespit etme yeteneğine dayanır. İmmünoterapi; özgüllüğü, uzunsüreli etkileri ve iyileşmeye olan katkıları sayesinde, kanser tedavisindekiyerini sağlamlaştırmaya devam etmektedir. Tümörler, anti-tümör immüntepkilerini inhibe etmek için bağışıklık kontrol noktaları olarak da bilineninhibitör reseptörleri kullanır. Birçok kişide immün-baskılamaya, SitotoksikT-Lenfosit-İlişkili Antijen-4 (CTLA-4) ve Programlanmış Ölüm-1 (PD-1)reseptörleri aracılık eder. CTLA-4 ve/veya PD-1 kontrol noktası inhibitörlerinihedefleyen monoklonal antikor (mAb) temelli terapilerin, birçok farklı malignintüründe, hastalara gözle görülür yararlar sağladığı gözlemlenmiştir. Buçalışmanın amacı, CTLA-4 ve PD-1/ PD-L1 tedavilerinin kanser tedavisindeki veimmünoterapideki yeri ile ilgili bilimsel çalışmaları incelemektir.
KW  - Kanser
KW  - immünoterapi
KW  - immün kontrol noktaları
KW  - CTLA-4
KW  - PD-1
KW  - PD-L1
N2  - Cancer immunotherapy aims to strengthen the humanimmune system to combat cancer and is based on the ability of the immune systemto detect the finest biochemical differences between cancer and normal cells.Immunotherapy's advantages among conventional methods are specificity to cancercells, long-term effects and contribution to healing. Tumors use inhibitoryreceptors, also known as immune control points, to inhibit anti-tumor immuneresponses. In many individuals, immunosuppression is mediated by CytotoxicT-Lymphocyte-Associated Antigen-4 (CTLA-4) and Programmed Death-1 (PD-1)receptors. Monoclonal antibody (mAb) based therapies targeting CTLA-4 and/orPD-1 control point inhibitors have been observed to provide significantbenefits to patients of many different types of malignancies. This study aimsto examine the scientific studies on the role of CTLA-4 and PD-1 / PD-L1 incancer therapy and immunotherapy.
CR  - A Shenoy, J. L. (2016). Cancer cells remodel themselves and vasculature to overcome the endothelial barrier. Cancer Lett., 380(2), 534–544. https://doi.org/10.1186/s40945-017-0033-9.Using
CR  - Apte, S. S., & Parks, W. C. (2015). Metalloproteinases: A parade of functions in matrix biology and an outlook for the future. Matrix Biology, 44–46, 1–6. https://doi.org/10.1016/j.matbio.2015.04.005
CR  - Aspeslagh, S., Solinas, C., Routy, B., Allard, B., Dupont, F. A., Buisseret, L., … Kok, M. (2018). Immuno-oncology-101: overview of major concepts and translational perspectives. Seminars in Cancer Biology, 52(February), 1–11. https://doi.org/10.1016/j.semcancer.2018.02.005
CR  - Baxter, E., Windloch, K., Gannon, F., & Lee, J. S. (2014). Epigenetic regulation in cancer progression. Cell and Bioscience, 4(1). https://doi.org/10.1186/2045-3701-4-45
CR  - Blomberg, O. S., Spagnuolo, L., & de Visser, K. E. (2018). Immune regulation of metastasis: mechanistic insights and therapeutic opportunities. Disease Models & Mechanisms, 11(10), dmm036236. https://doi.org/10.1242/dmm.036236
CR  - Bourboulia, D., & Stetler-Stevenson, W. G. (2010). Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs): Positive and negative regulators in tumor cell adhesion. Seminars in Cancer Biology, 20(3), 161–168. https://doi.org/10.1016/j.semcancer.2010.05.002
CR  - Boussiotis, V. A. (2016). Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway. The New England Journal of Medicine, 375(18), 1767–1778. https://doi.org/10.1056/NEJMra1514296
CR  - Campbell, R. (2013). Biyoloji (9th ed.). Istanbul: Palme Yayıncılık.
CR  - Caroline Bonnans, Jonathan Chou, Z. W. (2014). Remodelling the extracellular matrix in development and disease. Nat Rev Mol Cell Biol., 15(12), 786–801. https://doi.org/10.1038/nrm3904.Remodelling
CR  - Catalano, V., Turdo, A., Di Franco, S., Dieli, F., Todaro, M., & Stassi, G. (2013). Tumor and its microenvironment: A synergistic interplay. Seminars in Cancer Biology, 23(6), 522–532. https://doi.org/10.1016/j.semcancer.2013.08.007
CR  - Chiarugi, P., & Cirri, P. (2016). Metabolic exchanges within tumor microenvironment. Cancer Letters, 380(1), 272–280. https://doi.org/10.1016/j.canlet.2015.10.027
CR  - Chowdhury, F., Dunn, S., Mitchell, S., Mellows, T., Ashton-Key, M., & Gray, J. C. (2015). PD-L1 and CD8 + PD1 + lymphocytes exist as targets in the pediatric tumor microenvironment for immunomodulatory therapy. OncoImmunology, 4(10), e1029701. https://doi.org/10.1080/2162402X.2015.1029701
CR  - Church, S. E., & Galon, J. (2015). Tumor Microenvironment and Immunotherapy: The Whole Picture Is Better Than a Glimpse. Immunity, 43(4), 631–633. https://doi.org/10.1016/j.immuni.2015.10.004
CR  - Deryugina, E. I., & Quigley, J. P. (2015). Tumor angiogenesis: MMP-mediated induction of intravasation- and metastasis-sustaining neovasculature. Matrix Biology, 44–46, 94–112. https://doi.org/10.1016/j.matbio.2015.04.004
CR  - Doan, M. V. W. (2017). İmmünoloji (2nd ed.). Istanbul: Nobel Tıp Kitabevleri.
CR  - Erdogan, B., & Webb, D. J. (2017). Cancer-associated fibroblasts modulate growth factor signaling and extracellular matrix remodeling to regulate tumor metastasis. Biochem Soc Trans., 45(1), 229–236. https://doi.org/10.1042/BST20160387.Cancer-associated
CR  - Foy, S. P., Mandl, S. J., dela Cruz, T., Cote, J. J., Gordon, E. J., Trent, E., … Rountree, R. B. (2016). Poxvirus-based active immunotherapy synergizes with CTLA-4 blockade to increase survival in a murine tumor model by improving the magnitude and quality of cytotoxic T cells. Cancer Immunology, Immunotherapy, 65(5), 537–549. https://doi.org/10.1007/s00262-016-1816-7
CR  - Gibney, G. T., Weiner, P. L. M., Atkins, P. M. B., & Comprehensive, L. (2016). Predictive biomarkers for checkpoint inhibitor-based immunotherapy. Lancet Oncol., 17(12), 542–551. https://doi.org/10.1016/S1470-2045(16)30406-5.Predictive
CR  - Hamanishi, J., Mandai, M., Matsumura, N., Abiko, K., Baba, T., & Konishi, I. (2016). PD-1/PD-L1 blockade in cancer treatment: perspectives and issues. International Journal of Clinical Oncology, 21(3), 462–473. https://doi.org/10.1007/s10147-016-0959-z
CR  - Hirata, E., & Sahai, E. (2017). Tumor Microenvironment and Differential. Cold Spring Harb Perspect Med Doi: https://doi.org/10.1101/cshperspect.a026781
CR  - Hui, L., & Chen, Y. (2015). Tumor microenvironment: Sanctuary of the devil. Cancer Letters, 368(1), 7–13. https://doi.org/10.1016/j.canlet.2015.07.039
CR  - Ivey, J. W., Bonakdar, M., Kanitkar, A., Davalos, R. V., & Verbridge, S. S. (2016). Improving cancer therapies by targeting the physical and chemical hallmarks of the tumor microenvironment. Cancer Letters, 380(1), 330–339. https://doi.org/10.1016/j.canlet.2015.12.019
CR  - Joosse, S. A., Gorges, T. M., & Pantel, K. (2015). Biology, detection, and clinical implications of circulating tumor cells. EMBO Molecular Medicine, 7(1), 1–11. https://doi.org/10.15252/emmm.201303698
CR  - Kenny, P. A., Lee, G. Y., & Bissell, M. J. (2007). Targeting the tumor microenvironment. Frontiers in Bioscience, 12, 3468–3474.
CR  - Li, Y., Li, F., Jiang, F., Lv, X., Zhang, R., Lu, A., & Zhang, G. (2016). A mini-review for cancer immunotherapy: Molecular understanding of PD-1/ PD-L1 pathway & translational blockade of immune checkpoints. International Journal of Molecular Sciences, 17(7), 1–22. https://doi.org/10.3390/ijms17071151
CR  - Lo, B., & Abdel-Motal, U. M. (2017, December 1). Lessons from CTLA-4 deficiency and checkpoint inhibition. Current Opinion in Immunology. Elsevier Ltd. https://doi.org/10.1016/j.coi.2017.07.014
CR  - Madigan, J. M. M. (2012). Mikroorganizmaların Biyolojisi (11th ed.). Istanbul: Palme Yayıncılık.
CR  - Majzner, R. G., Simon, J. S., Grosso, J. F., Martinez, D., Pawel, B. R., Santi, M., … Maris, J. M. (2017). Assessment of programmed death-ligand 1 expression and tumor-associated immune cells in pediatric cancer tissues. Cancer, 123(19), 3807–3815. https://doi.org/10.1002/cncr.30724
CR  - Malik, R., Lelkes, P. I., & Cukierman, E. (2015). BIOMECHANICAL and BIOCHEMICAL REMODELING of STROMAL EXTRACELLULAR MATRIX IN CANCER. Trends Biotechnol., 33(4), 230–236. https://doi.org/10.1016/j.tibtech.2015.01.004.BIOMECHANICAL
CR  - Marcucci, F., Rumio, C., & Corti, A. (2017). Tumor cell-associated immune checkpoint molecules – Drivers of malignancy and stemness. Biochimica et Biophysica Acta - Reviews on Cancer, 1868(2), 571–583. https://doi.org/10.1016/j.bbcan.2017.10.006
CR  - Masuda, T., Hayashi, N., Iguchi, T., Ito, S., Eguchi, H., & Mimori, K. (2016). Clinical and biological significance of circulating tumor cells in cancer. Molecular Oncology, 10(3), 408–417. https://doi.org/10.1016/j.molonc.2016.01.010
CR  - Melo, F. H. M. de, Oliveira, J. S., Sartorelli, V. O. B., & Montor, W. R. (2018). Cancer Chemoprevention: Classic and Epigenetic Mechanisms Inhibiting Tumorigenesis. What Have We Learned So Far? Frontiers in Oncology, 8(December), 1–15. https://doi.org/10.3389/fonc.2018.00644
CR  - Meng, Y., Liang, H., Hu, J., Liu, S., Hao, X., Wong, M. S. K., … Hu, L. (2018). PD-L1 Expression Correlates With Tumor Infiltrating Lymphocytes And Response To Neoadjuvant Chemotherapy In Cervical Cancer. Journal of Cancer, 9(16), 2938–2945. https://doi.org/10.7150/jca.22532
CR  - Michael W Pickup, Janna K Mouw, V. M. W. (2014). The extracellular matrix modulates the hallmarks of cancer. EMBO Reports, 15, 1243–1253. https://doi.org/10.15252/embr.201439246
CR  - Missiaen, R., Mazzone, M., & Bergers, G. (2018). The reciprocal function and regulation of tumor vessels and immune cells offers new therapeutic opportunities in cancer. Seminars in Cancer Biology, 52(June), 107–116. https://doi.org/10.1016/j.semcancer.2018.06.002
CR  - Multhaupt, H. A. B., Leitinger, B., Gullberg, D., & Couchman, J. R. (2016). Extracellular matrix component signaling in cancer. Advanced Drug Delivery Reviews, 97, 28–40. https://doi.org/10.1016/j.addr.2015.10.013
CR  - Nallasamy, P., Chava, S., Verma, S. S., Mishra, S., Gorantla, S., Coulter, D. W., … Challagundla, K. B. (2018). PD-L1, inflammation, non-coding RNAs, and neuroblastoma: Immuno-oncology perspective. Seminars in Cancer Biology, 52(July 2017), 53–65. https://doi.org/10.1016/j.semcancer.2017.11.009
CR  - Okazaki, T., Chikuma, S., Iwai, Y., Fagarasan, S., & Honjo, T. (2013). A rheostat for immune responses: The unique properties of PD-1 and their advantages for clinical application. Nature Immunology, 14(12), 1212–1218. https://doi.org/10.1038/ni.2762
CR  - Ott, P. A., Hodi, F. S., & Robert, C. (2013). CTLA-4 and PD-1/PD-L1 blockade: New immunotherapeutic modalities with durable clinical benefit in melanoma patients. Clinical Cancer Research, 19(19), 5300–5309. https://doi.org/10.1158/1078-0432.CCR-13-0143
CR  - Parkin, D. M., Bray, F., Ferlay, J., & Pisani, P. (2005). Global Cancer Statistics, 2002. CA: A Cancer Journal for Clinicians, 55(2), 74–108. https://doi.org/10.3322/canjclin.55.2.74
CR  - Potapova T, Zhu J, L. R. (2013). Aneuploidy and chromosomal instability: a vicious cycle driving cellular evolution and cancer genome chaos. Cancer Metastasis Rev., 32(0). https://doi.org/10.1249/MSS.0000000000000294
CR  - Rainero, E. (2016). Extracellular matrix endocytosis in controlling matrix turnover and beyond: emerging roles in cancer. Biochemical Society Transactions, 44(5), 1347–1354. https://doi.org/10.1042/bst20160159
CR  - Rangel-Sosa, M. M., Aguilar-Córdova, E., & Rojas-Martínez, A. (2017, September 30). Immunotherapy and gene therapy as novel treatments for cancer. Colombia Medica (Cali, Colombia). https://doi.org/10.25100/cm.v48i3.2997
CR  - Rejniak, K. A. (2016). Circulating Tumor Cells: When a Solid Tumor Meets a Fluid Microenvironment. Advances in Experimental Medicine and Biology, 936, 93–106. https://doi.org/10.1007/978-1-4614-1445-2_6
CR  - Rowshanravan, B., Halliday, N., & Sansom, D. M. (2018, January 4). CTLA-4: A moving target in immunotherapy. Blood. American Society of Hematology. https://doi.org/10.1182/blood-2017-06-741033
CR  - Shay, G., Lynch, C. C., & Fingleton, B. (2015). Moving targets: Emerging roles for MMPs in cancer progression and metastasis. Matrix Biology, 44–46, 200–206. https://doi.org/10.1016/j.matbio.2015.01.019
CR  - Taube, J. M., Galon, J., Sholl, L. M., Rodig, S. J., Cottrell, T. R., Giraldo, N. A., … David, L. (2018). Implications of the tumor immune microenvironment for staging and therapeutics. Mod Pathol., 31(2), 214–234. https://doi.org/10.1038/modpathol.2017.156.Implications
CR  - Van Doren, S. R. (2015). Matrix metalloproteinase interactions with collagen and elastin. Matrix Biology, 44–46(i), 224–231. https://doi.org/10.1016/j.matbio.2015.01.005
CR  - Van Hooren, L., Sandin, L. C., Moskalev, I., Ellmark, P., Dimberg, A., Black, P., … Mangsbo, S. M. (2017). Local checkpoint inhibition of CTLA-4 as a monotherapy or in combination with anti-PD1 prevents the growth of murine bladder cancer. European Journal of Immunology, 47(2), 385–393. https://doi.org/10.1002/eji.201646583
CR  - Walker, C., Mojares, E., & del Río Hernández, A. (2018). Role of Extracellular Matrix in Development and Cancer Progression. International Journal of Molecular Sciences (Vol. 19). https://doi.org/10.3390/ijms19103028
CR  - Walker, L. S. K. (2013, September). Treg and CTLA-4: Two intertwining pathways to immune tolerance. Journal of Autoimmunity. https://doi.org/10.1016/j.jaut.2013.06.006
CR  - Walker, L. S. K., & Sansom, D. M. (2015, February 1). Confusing signals: Recent progress in CTLA-4 biology. Trends in Immunology. Elsevier Ltd. https://doi.org/10.1016/j.it.2014.12.001
CR  - Wang, L.-H., Wu, C.-F., Rajasekaran, N., & Shin, Y. K. (2018). Loss of Tumor Suppressor Gene Function in Human Cancer: An Overview. Cellular Physiology and Biochemistry, 2647–2693. https://doi.org/10.1159/000495956
CR  - Weber, C. E., & Kuo, P. C. (2012). The tumor microenvironment. Surgical Oncology, 21(3), 172–177. https://doi.org/10.1016/j.suronc.2011.09.001
CR  - Wu, T., & Dai, Y. (2017). Tumor microenvironment and therapeutic response. Cancer Letters, 387, 61–68. https://doi.org/10.1016/j.canlet.2016.01.043
CR  - Yang, L., & Lin, P. C. (2017). Mechanisms that drive inflammatory tumor microenvironment, tumor heterogeneity, and metastatic progression. Seminars in Cancer Biology, 47(July), 185–195. https://doi.org/10.1016/j.semcancer.2017.08.001
CR  - Zhang, X., Wang, C., Wang, J., Hu, Q., Langworthy, B., Ye, Y., Gu, Z. (2018). PD-1 Blockade Cellular Vesicles for Cancer Immunotherapy. Advanced Materials (Deerfield Beach, Fla.), 30(22), e1707112. https://doi.org/10.1002/adma.201707112
UR  - https://doi.org/10.29048/makufebed.569375
L1  - https://dergipark.org.tr/en/download/article-file/880828
ER  -